Compare NYXH & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NYXH | ARCT |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.9M | 163.4M |
| IPO Year | 2021 | 2019 |
| Metric | NYXH | ARCT |
|---|---|---|
| Price | $1.42 | $5.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $9.33 | ★ $24.11 |
| AVG Volume (30 Days) | 175.2K | ★ 531.6K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | $213.98 | N/A |
| Revenue Next Year | $126.25 | $12.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $5.50 |
| 52 Week High | $8.59 | $24.14 |
| Indicator | NYXH | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 29.42 | 34.51 |
| Support Level | $1.26 | N/A |
| Resistance Level | $1.70 | $7.93 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 2.70 | 16.86 |
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.